EGFR and adenocarcinoma: Because mutational status of EGFR has been shown in select studies to correlate with tumor response to erlotinib and gefitinib [15,28], we chose to further validate our model on a series of resected adenocarcinomas for which mutational status, as well as pEGFR status was known.